The review frames metabolic syndrome as more than a cluster of isolated risks. The authors reported that when obesity, dyslipidemia, hypertension and insulin resistance coexist they interactively amplify processes that favor Alzheimer's disease pathology. Short, direct claim: combined metabolic insults confer greater risk than single components. The review emphasized systemic patterns—peripheral metabolic dysfunction propagates into the brain by multiple routes, accelerating amyloid and tau-related processes according to the authors.
Data indicated several cellular pathways through which MetS promotes neurodegeneration. Insulin resistance and cerebral energy dysregulation were presented as primary drivers, impairing neuronal glucose utilization and synaptic function. Oxidative stress and mitochondrial dysfunction were described as parallel mechanisms that damage neurons and reduce cellular resilience. Neuroinflammation, with activation of microglia and astrocytes, was described as a sustained amplifier of damage rather than a transient response. The review also covered vascular dysfunction—endothelial impairment and blood–brain barrier disruption—that compounds neuronal injury. The authors noted that dysregulation of the renin‑angiotensin system further perturbs cerebral perfusion and inflammatory balance.
The group highlighted emerging regulatory modalities, including the gut‑brain axis, as a mediator of systemic-to-central signaling. Gut microbiota alterations were discussed as modulators of inflammation, metabolic signaling and blood‑brain barrier integrity. Epigenetic reprogramming was identified as a mechanism by which peripheral metabolic stress can induce persistent changes in gene expression within the brain. The authors also described sex differences and hormonal effects that may alter vulnerability or resilience to MetS‑related AD processes. Finally, a senescent microenvironment—systemic cellular aging—was presented as a context that amplifies neuroinflammatory and degenerative cascades.
Among signaling pathways, the review focused on glycogen synthase kinase‑3β (GSK‑3β) as a central integrator of metabolic and neurodegenerative signals. The authors argued that multiple MetS‑related perturbations—insulin resistance, oxidative stress and inflammatory mediators—converge on GSK‑3β to dysregulate tau phosphorylation and other downstream effectors linked to AD pathology. The narrative presented GSK‑3β not as a single cause but as a hub where diverse upstream disturbances intersect, potentially offering a mechanistic target for interventions that address multiple upstream metabolic abnormalities simultaneously.
The review proposed a layered, precision prevention framework aimed at MetS‑associated AD. Lifestyle modification was positioned as foundational—diet, physical activity and metabolic control to reduce peripheral drivers. The authors suggested metabolic drug repurposing as a complementary axis, though the review did not enumerate specific drugs with proven disease‑modifying efficacy in AD patients. Gut microbiota regulation and targeted modulation of the gut‑brain axis were advanced as promising approaches to reduce systemic inflammation and restore metabolic signaling. Anti‑aging therapies and interventions addressing cellular senescence were also discussed as potential modulators of the aging microenvironment that promotes AD. Finally, the review proposed biomarker‑guided subtype classification to match interventions to patient-specific metabolic-AD phenotypes; however, the review did not specify validated biomarker panels or threshold values for clinical use.
The authors acknowledged key gaps. Much of the mechanistic evidence derives from preclinical models; translation to human AD risk and progression remains to be validated. The review did not provide clinical trial dosing, nor did it list specific repurposed agents with confirmed cognitive benefit in human trials—those details were not reported. Biomarker‑guided subtype schemes were proposed conceptually, yet thresholds, sensitivity, specificity and prospective validation studies remain absent. The review called for integrative, longitudinal research to test whether targeting peripheral metabolic networks—alongside central mechanisms such as GSK‑3β—can prevent or slow AD in defined patient subgroups. These are concrete next research steps identified by the authors rather than definitive clinical recommendations.